Medication info
Pregabalin Capsule 50 mg (Pregabalin)

Pregabalin Capsule 50 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›50mg / 1 capsule
Manufacturer / importer
Cosmax Pharma Co., Ltd.
Appearance
A hard capsule with a white to pale yellow powder inside, dark blue on the upper part and white on the lower part
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201901231 · Approved 2019.02.26 · Insurance code 055100840

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section 5, “Patients with Renal Impairment”). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg daily. Depending on the response and tolerability of the individual patient, the dose may be increased to 300mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg daily. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg daily. Depending on the response and tolerability of the individual patient, the dose may be increased to 300mg daily after 1 week. After an additional week, it may be increased to the target dose of 600mg daily. If the target daily dose is not tolerated, dose reduction may be considered (see section 4, “Discontinuation”). 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150mg daily. Depending on the response and tolerability of the individual patient, the dose may be increased to 300mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300mg∼450mg daily. The initial dose is 75mg twice daily (150mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150mg twice daily (300mg daily). For patients who do not experience sufficient benefit at a dose of 300mg daily, the dose may be increased within 1 week to 225mg twice daily (450mg daily). Clinical studies have also been conducted with a dose of 600mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450mg daily are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25-100, single dose TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: A supplemental dose means an additional dose administered as a single dose. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. *: For women, multiply the result obtained from the above calculation by 0.85. 6. Patients with hepatic impairment No dosage adjustment is needed in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12∼17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Cosmax Pharma Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in epilepsy patients, with or without secondary generalized symptoms. Moreover, it is effective for the treatment of fibromyalgia. In summary, this drug helps improve symptoms associated with neuropathic pain, epilepsy, and fibromyalgia.

How to take

Adult dose

Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section 5, “Patients with Renal Impairment”). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg daily. Depending on the response and tolerability of the individual patient, the dose may be increased to 300mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg daily. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg daily. Depending on the response and tolerability of the individual patient, the dose may be increased to 300mg daily after 1 week. After an additional week, it may be increased to the target dose of 600mg daily. If the target daily dose is not tolerated, dose reduction may be considered (see section 4, “Discontinuation”). 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150mg daily. Depending on the response and tolerability of the individual patient, the dose may be increased to 300mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300mg∼450mg daily. The initial dose is 75mg twice daily (150mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150mg twice daily (300mg daily). For patients who do not experience sufficient benefit at a dose of 300mg daily, the dose may be increased within 1 week to 225mg twice daily (450mg daily). Clinical studies have also been conducted with a dose of 600mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450mg daily are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25-100, single dose TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: A supplemental dose means an additional dose administered as a single dose. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. *: For women, multiply the result obtained from the above calculation by 0.85. 6. Patients with hepatic impairment No dosage adjustment is needed in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12∼17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behavior; therefore, if mood changes or symptoms of depression occur during treatment, consult a physician immediately. Patients with hypersensitivity to this drug or genetic issues such as lactose intolerance should not take it. Diabetic patients may need to adjust their blood glucose medication doses due to weight gain after taking this drug. If symptoms of angioedema occur, discontinue use immediately. Elderly patients may need to be cautious as dizziness or drowsiness can increase the risk of falls. This drug may cause blurred vision or changes in vision, and if these symptoms occur, consult a physician. Discontinuing the medication abruptly can lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety; thus, it should be tapered off according to a physician's instructions. Patients with a history of substance abuse should be carefully monitored due to the potential risk of misuse. Patients with reduced kidney function may require dose adjustment. Patients with heart disease should be cautious regarding the potential for heart failure when taking this medication. Taking this drug with opioid analgesics may increase the risk of central nervous system depression, so caution is required when used together. This drug may cause respiratory depression, and patients with respiratory diseases or kidney disorders should exercise caution when using it. During early pregnancy, there is a risk of fetal malformation, so pregnant women should not take this medication, and women of childbearing age should use effective contraception. If breastfeeding, this medication may be secreted in breast milk and affect the baby, so breastfeeding should be discontinued or a physician should be consulted. When driving or operating machinery, due to risks from dizziness or drowsiness, caution should be exercised until these symptoms resolve after taking the drug. Severe skin reactions may rarely occur; if symptoms such as skin rash or swelling appear, discontinue use immediately and consult healthcare professionals. In cases of overdose, symptoms like confusion, drowsiness, and seizures may occur; seek appropriate medical treatment immediately.

Side effects

  • Suicidal ideation
  • suicidal behavior
  • depression
  • abnormal mood and behavioral changes
  • angioedema
  • facial swelling
  • perioral swelling
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 202 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • visual changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual arousal disorder
  • restlessness
  • agitation
  • mood instability
  • emotional blunting
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • uncontrollable urges
  • apathy
  • ataxia
  • motor coordination disorders
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory reduction
  • sedation
  • somnolence
  • cognitive dysfunction
  • nystagmus
  • speech disorders
  • myoclonus
  • reflex reduction
  • motor disturbances
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • action tremors
  • syncope
  • confusion
  • motor retardation
  • olfactory disturbances
  • loss of taste
  • writing disabilities
  • blurred vision
  • diplopia
  • loss of peripheral vision
  • visual disturbances
  • visual field defects
  • photophobia
  • dry eyes
  • eye swelling
  • vision reduction
  • eye pain
  • eye fatigue
  • increased tearing
  • eye irritation
  • mydriasis
  • during tremors
  • changes in depth perception
  • strabismus
  • bright vision
  • vertigo
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal bloating
  • constipation
  • dry mouth
  • flatulence
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory reduction
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falling
  • feeling drunk
  • altered sensations
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased creatine phosphokinase levels
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • malaise
  • delirium
  • paralysis
  • affective disorders
  • drowsiness
  • confusion
  • agitation
  • restlessness
  • worsening of seizures
  • bloody stools
  • tinnitus
  • sleep disorders
  • skin diseases
  • increased BUN
  • dysuria

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. Additionally, it is important to store it at a cool temperature between 15 degrees Celsius and 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

A hard capsule with a white to pale yellow powder inside, dark blue on the upper part and white on the lower part

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.